Procarbazine: Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
No edit summary
No edit summary
Line 9: Line 9:
|notes=Combination of Temodar and procarbazine showed a high percentage of tumor regressions, suggesting effectiveness.
|notes=Combination of Temodar and procarbazine showed a high percentage of tumor regressions, suggesting effectiveness.
|category=Other Chemotherapy and Cancer Drugs
|category=Other Chemotherapy and Cancer Drugs
|toxicity_level=4
|toxicity_explanation=The drug Procarbazine is considered quite toxic. This rating is based on the common side effects like hematological toxicity, which refers to potential harm to your blood cells, nausea, and neurological effects such as headache or dizziness. These side effects are relatively common and could significantly affect your day-to-day life. Remember, all treatments come with potential risks, and it's important to discuss these with your doctor.
}}
}}

Revision as of 09:55, 27 March 2024

Property Information
Drug Name Procarbazine
FDA Approval Yes
Used for Glioblastoma
Clinical Trial Phase Not specified
Clinical Trial Explanation Not specified
Common Side Effects Hematological toxicity, nausea, and neurological effects
OS without Not specified
OS with Not specified
PFS without Not specified
PFS with Not specified
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level 4
Toxicity Explanation The drug Procarbazine is considered quite toxic. This rating is based on the common side effects like hematological toxicity, which refers to potential harm to your blood cells, nausea, and neurological effects such as headache or dizziness. These side effects are relatively common and could significantly affect your day-to-day life. Remember, all treatments come with potential risks, and it's important to discuss these with your doctor.

Notes: Combination of Temodar and procarbazine showed a high percentage of tumor regressions, suggesting effectiveness.


From Ben Williams Book: Not specified

Loading comments...